...3C-like protease inhibitor PF-07304814 in Phase I testing. Spurred by a desire not to get caught flat-footed...

...good cause exception in this case falls flat,”...

...market for antibiotics, will pay manufacturers a flat...

...about $47 billion, and has remained relatively flat...

...for Economic Cooperation and Development, plus a flat...

...for Economic Cooperation and Development, plus a flat...

...Spinraza, came in at $495 million, short of analysts’ $511 million consensus. Spinraza sales were flat...

...Biotech midcaps the single bright spot amongst mostly flat valuations in 3Q20 By stephen hansen, associate...
...stephen hansen, associate editor The third quarter saw most tiers of the biotech sector trade flat...
...expiration of the lock-up period for IPO investors.The $1-$4.9 billion market cap group were largely flat...

...have played this.” While biotech indexes were largely flat...

...Flipt, a startup that charges a transparent flat...
...with a plan where sponsors pay a flat...